Ovarian tumors of low malignant potential

Trimble, Edward L.; Trimble, Cornelia L.

doi:10.1007/s11864-001-0052-2

Cited by 14 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ninety percent of BOTs diagnosed in pregnant women are stage I (31). In our study, FIGO stage I accounted for 92%, which is consistent with the literature.…”

Section: Histological Diagnosis and Recurrencesupporting

confidence: 92%

Management of borderline ovarian tumors in pregnancy: A Retrospective Analysis

Hu²,

Cui³

2023

Preprint

View full text Add to dashboard Cite

Objective: To evaluate the clinical and histopathological characteristics of borderline ovarian tumors in pregnancy, the prognosis after surgery at different stages of pregnancy, and maternal and neonatal outcomes, with the aim of providing a basis for the optimal management strategy of borderline ovarian tumors in pregnancy. Materials and Methods: Twenty-fourpatients with borderline ovarian tumors who were treated from January 2011 to March 2022 and diagnosed during pregnancy or postpartumwere enrolled. All medical records were reviewed to extract clinical and obstetric characteristics, histological tumor characteristics, surgical procedure, and follow-up. Results: Four patients (17%) were diagnosed during the first trimester of pregnancy, 6 (25%) during the second trimester, 12 (50%) during the third trimester, and 2 (8%) in postpartum. More Unilateral cystectomies (46%) were performed than unilateral cystectomies (29%), and more unilateral cystectomies plus contralateral cystectomies (17%) were performed than bilateral cystectomies (8%). Three patients with ruptured masses were found intraoperatively in the third trimester. Serous mucinous borderline ovarian tumorsaccountedfor 25% (6/24), and mixed borderline ovarian tumors (mucous/translucent) accounted for 4% (1/24). FIGO stage I accounted for 92% of the patients (22/24). Eight percentwere classified (2/24) as stage III, both of which were bilateral SBT-micro papilla subtypes. Full-term pregnancies accounted for 87.5% of the patients (21/24). Of the 21 patients who delivered, 43% (9/21) had a normal delivery. A total of 19 newborns had a one-minute Apgar scoreof 10. Recurrence occurred in 12.5% of the patients (3/24). Five patients had a previous history of borderline ovarian tumor. Two patients (8%) had two episodes of borderline ovarian tumor before the current pregnancy, and three (13%) had one episode. No postoperative malignancy was found in any patient. Conclusion: Pregnancy does not worsen the prognosis of borderline ovarian tumors, even with multiple recurrences, and progression does not occur even with conservative observation throughout pregnancy and management after delivery. Borderline ovarian tumorsdo not affect the mode of delivery. There were no differences in maternal and neonatal pregnancy outcomes at different stages of pregnancy or in postpartum management of borderline ovarian tumors.

show abstract

“…Ninety percent of BOTs diagnosed in pregnant women are stage I (31). In our study, FIGO stage I accounted for 92%, which is consistent with the literature.…”

Section: Histological Diagnosis and Recurrencesupporting

confidence: 92%

Management of borderline ovarian tumors in pregnancy: A Retrospective Analysis

Hu²,

Cui³

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…LMP tumors display atypical epithelial proliferation with nuclear atypia and frequent extraovarian lesions (so-called ''implants'') in the peritoneal cavity and lymph nodes yet lack (by definition) destructive stromal invasion in the notional primary neoplasm. They are considerably less aggressive than high-grade serous carcinomas (4), and progressive disease is dependent on the presence and features of the extraovarian lesions-the true nature of which, therefore, remains controversial. Whereas the 5-year survival for patients diagnosed with advanced high-grade serous ovarian carcinoma is <45%, women with ''high-stage'' LMP tumors have a more favorable prognosis, with some reports describing 5-year survival as high as 95% (3).…”

Section: Introductionmentioning

confidence: 99%

Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

Anglesio

Arnold²,

George³

et al. 2008

Molecular Cancer Research

111

View full text Add to dashboard Cite

Approximately, 10% to 15% of serous ovarian tumors fall into the category designated as tumors of low malignant potential (LMP). Like their invasive counterparts, LMP tumors may be associated with extraovarian disease, for example, in the peritoneal cavity and regional lymph nodes. However, unlike typical invasive carcinomas, patients generally have a favorable prognosis. The mutational profile also differs markedly from that seen in most serous carcinomas. Typically, LMP tumors are associated with KRAS and BRAF mutations. Interrogation of expression profiles in serous LMP tumors suggested overall redundancy of RAS-MAPK pathway mutations and a distinct mechanism of oncogenesis compared with high-grade ovarian carcinomas. Our findings indicate that activating mutation of the RAS-MAPK pathway in serous LMP may be present in >70% of cases compared with f12.5% in serous ovarian carcinomas. In addition to mutations of KRAS (18%) and BRAF (48%) mutations, ERBB2

show abstract

“…Borderline tumors have a wide histological variety, as in ovarian epithelial carcinoma [3,4]. Most cases are serous or mucinous.…”

Section: Discussionmentioning

confidence: 99%

Borderline Ovarian Tumor with Severe Dyspnea in a 79 Year Old Patient

Manuel¹,

Imane²,

Amparo³

et al. 2017

Gynecol Obstet Case Rep

View full text Add to dashboard Cite

Borderline ovarian tumors (also called tumors of malignancy potential) are heterogeneous team of lesions histologically defined by atypical epithelial proliferation without stromal invasion.The majority of those tumors use to have a good forecast, what is not so habitual is that if the tumor has a big size in on elderly patient with basic cardiopulmonary pathology it can be a urgent situation that endangers the life of the patient.We present a clinical case of a pluripathology 79 years old female who comes for consultation with tachycardiatachypnea, incapacity for supine decubitus and dyspnea on minimal effort. A large ovarian-dependent abdominal tumor is diagnosed. Borderline left ovary tumor of 42 × 36 × 7 cm is removed. Good postoperative evolution. Disappearance of all respiratory and digestive symptoms after surgery. Evolution after one year remained asymptomatic and free of disease.

show abstract

Ovarian tumors of low malignant potential

Cited by 14 publications

References 30 publications

Management of borderline ovarian tumors in pregnancy: A Retrospective Analysis

Management of borderline ovarian tumors in pregnancy: A Retrospective Analysis

Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors

Borderline Ovarian Tumor with Severe Dyspnea in a 79 Year Old Patient

Contact Info

Product

Resources

About